A scalable platform for human embryonic stem cell (hESC)-derived cardiomyocyte (CM) production can provide a readily available source of CMs for cell therapy, drug screening, and cardiotoxicity tests. We have designed and optimized a scalable platform using microcarrier cultures in serum-free media supplemented with SB203580 mitogen-activated protein kinase-inhibitor. Different microcarriers (DE-53, Cytodex-1 and 3, FACT, and TOSOH-10) were used to investigate the effects of type, size, shape, and microcarrier concentrations on the differentiation efficiency. hESCs propagated on TOSOH-10 (protamine derivatized 10-μm beads) at the concentration of 0.125 mg/mL produced 80% beating aggregates, threefold cell expansion, and 20% of CMs (determined by fluorescence-activated cell sorting for myosin heavy chain and α-actinin expression). The ratio of CM/hESC seeded in this system was 0.62 compared to 0.22 in the embryoid body control cultures. The platform robustness has been tested with HES-3 and H1 cell lines, and its scalability was demonstrated in suspended spinner cultures. However, spinner culture yields dropped to 0.33 CM/hESC probably due to shear stress causing some cell death. Cells dissociated from differentiated aggregates showed positive staining for cardio-specific markers such as α-actinin, myosin heavy and light chain, troponin I, desmin, and emilin-2. Finally, CM functionality was also shown by QT-prolongation (QTempo) assay with/without Astemizole. This study represents a new scalable bioprocessing system for CM production using reagents that can comply with Good Manufacturing Practice.
Get full access to this article
View all access options for this article.
References
1.
Perez-IlzarbeM., AgbulutO., PelachoB., CiorbaC., Jose-EnerizE.S., DesnosM., HagegeA.A., ArandaP., AndreuE.J., MenascheP., ProsperF.Characterization of the paracrine effects of human skeletal myoblasts transplanted in infarcted myocardium. Eur J Heart Fail, 10:1065. 2008.
2.
FujiiT., YauT.M., WeiselR.D., OhnoN., MickleD.A.G., ShionoN., OzawaT., MatsubayashiK., LiR.K.Cell transplantation to prevent heart failure: a comparison of cell types. Ann Thorac Surg, 76:2062. 2003.
3.
StuckeyD.J., CarrC.A., Martin-RendonE., TylerD.J., WillmottC., CassidyP.J., HaleS.J.M., SchneiderJ.E., TattonL., HardingS.E., RaddaG.K., WattS., ClarkeK.Iron particles for noninvasive monitoring of bone marrow stromal cell engraftment into and isolation of viable engrafted donor cells from the heart. Stem Cells, 24:1968. 2006.
4.
YoungP.P., VaughanD.E., HatzopoulosA.K.Biologic properties of endothelial progenitor cells and their potential for cell therapy. Prog Cardiovasc Dis, 49:421. 2005.
5.
Abdel-LatifA., BolliR., TleyjehI.M., MontoriV.M., PerinE.C., HornungC.A., Zuba-SurmaE.K., Al MallahM., DawnB.Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med, 167:989. 2007.
6.
AmadoL.C., SchuleriK.H., SaliarisA.P., BoyleA.J., HelmR., OskoueiB., CentolaM., EneboeV., YoungR., LimaJ.A.C., LardoA.C., HeldmanA.W., HareJ.M.Multimodality non-invasive imaging demonstrates in vivo cardiac regeneration after mesenchymal stem cell therapy. J Am Coll Cardiol, 48:2116. 2006.
7.
GnecchiM., HeH.M., LiangO.D., MeloL.G., MorelloF., MuH., NoiseuxN., ZhangL.N., PrattR.E., IngwallJ.S., DzauV.J.Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med, 11:367. 2005.
8.
LaflammeM.A., MurryC.E.Regenerating the heart. Nat Biotechnol, 23:845. 2005.
9.
KehatI., KhimovichL., CaspiO., GepsteinA., ShoftiR., ArbelG., HuberI., SatinJ., Itskovitz-EldorJ., GepsteinL.Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat Biotechnol, 22:1282. 2004.
DaiW., FieldL.J., RubartM., ReuterS., HaleS.L., ZweigerdtR., GraichenR.E., KayG.L., JyralaA.J., ColmanA., DavidsonB.P., PeraM., KlonerR.A.Survival and maturation of human embryonic stem cell-derived cardiomyocytes in rat hearts. J Mol Cell Cardiol, 43:504. 2007.
12.
van LaakeL.W., PassierR., DoevendansP.A., MummeryC.L.Human embryonic stem cell-derived cardiomyocytes and cardiac repair in rodents. Circ Res, 102:1008. 2008.
13.
BraamS.R., PassierR., MummeryC.L.Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery. Trends Pharmacol Sci, 30:536. 2009.
14.
van LaakeL.W., PassierR., den OudenK., SchreursC., Monshouwer-KlootsJ., Ward-van OostwaardD., van EchteldC.J., DoevendansP.A, MummeryC.L.Improvement of mouse cardiac function by hESC-derived cardiomyocytes correlates with vascularity but not graft size. Stem Cell Res, 3:106. 2009.
15.
PassierR., van LaakeL.W., MummeryC.L.Stem-cell-based therapy and lessons from the heart. Nature, 453:322. 2008.
16.
MurryC.E., ReineckeH., PabonL.M.Regeneration gaps: observations on stem cells and cardiac repair. J Am Coll Cardiol, 47:1777. 2006.
17.
ZweigerdtR.The art of cobbling a running pump—Will human embryonic stem cells mend broken hearts?Semin Cell Dev Biol, 18:794. 2007.
18.
SteelD., HyllnerJ., SartipyP.Cardiomyocytes derived from human embryonic stem cells—characteristics and utility for drug discovery. Curr Opin Drug Discov Dev, 12:133. 2009.
19.
JingD., ParikhA., CantyJ., TzanakakisE.S.Stem cells for heart cell therapies. Tissue Eng Part B, 14:393. 2008.
20.
PassierR., OostwaardD.W., SnapperJ., KlootsJ., HassinkR.J., KuijkE., RoelenB., de la RiviereA.B., MummeryC.Increased cardiomyocyte differentiation from human embryonic stem cells in serum-free cultures. Stem Cells, 23:772. 2005.
21.
BurridgeP.W., AndersonD., PriddleE., Barbadillo MuñozM.D., ChamberlainS., AllegrucciC., YoungL.E., DenningC.Improved human embryonic stem cell embryoid body homogeneity and cardiomyocyte differentiation from a novel V-96 plate aggregation system highlights interline variability. Stem Cells, 25:929. 2007.
22.
LaflammeM.A., ChenK.Y., NaumovaA.V., MuskheliV., FugateJ.A., DuprasS.K., ReineckeH., XuC., HassanipourM., PoliceS., O'SullivanC., CollinsL., ChenY., MinamiE., GillE.A., UenoS., YuanC., GoldJ., MurryC.E.Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol, 25:1015. 2007.
GraichenR., XuX., BraamS.R., BalakrishnanT., NorfizaS., SiehS., SooS.Y., ThamS.C., MummeryC., ColmanA., ZweigerdtR., DavidsonB.P.Enhanced cardiomyogenesis of human embryonic stem cells by a small molecular inhibitor of p38 MAPK. Differentiation, 76:357. 2008.
25.
XuX.Q., GraichenR., SooS.Y., BalakrishnanT., Bte RahmaS.N., SiehS., ThamS.C., FreundC., MooreJ., MummeryC., ColmanA., ZweigerdtR., DavidsonB.P.Chemically defined medium supporting cardiomyocyte differentiation of human embryonic stem cells. Differentiation, 76:958. 2008.
26.
SargentC.Y., BerguigJ.Y., McDevittT.C.Cardiomyogenic differentiation of embryoid bodies is promoted by rotary orbital suspension cultures. Tissue Eng Part A, 15:331. 2009.
27.
NiebrueggeS., NehringA., BarH., SchroederM., ZweigerdtR., LehmannJ.Cardiomyocyte production in mass suspension culture: embryonic stem cells as a source for great amounts of functional cardiomyocytes. Tissue Eng Part A, 14:1591. 2008.
BauwensC., YinT., DangS., PeeraniR., ZandstraP.W.Development of a perfusion fed bioreactor for embryonic stem cell-derived cardiomyocyte generation: oxygen-mediated enhancement of cardiomyocyte output. Biotechnol Bioeng, 90:452. 2005.
30.
NiebrueggeS., BauwensC.L., PeeraniR., ThavandiranN., MasseS., SevaptisidisE., NanthakumarK., WoodhouseK., HusainM., KumachevaE., ZandstraP.W.Generation of human embryonic stem cell-derived mesoderm and cardiac cells using size-specified aggregates in an oxygen-controlled bioreactor. Biotechnol Bioeng, 102:493. 2009.
31.
PhillipsB.W., HorneR., LayT.S., RustW.L., TeckT.T., CrookJ.M.Attachment and growth of human embryonic stem cells on microcarriers. J Biotechol, 138:24. 2008.
32.
AzarinS.M., PalecekS.P.Development of scalable culture systems for human embryonic stem cells. Biochem Eng J, 48:378. 2010.
33.
LockL.T., TzanakakisE.S.Expansion and differentiation of human embryonic stem cells to endoderm progeny in a microcarrier stirred-suspension culture. Tissue Eng Part A, 15:2051. 2009.
ChooA.B., PadmanabhanJ., ChinA.C., OhS.K.Expansion of pluripotent human embryonic stem cells on human feeders. Biotechnol Bioeng, 88:321. 2004.
36.
ChooA., PadmanabhanJ., ChinA., FongW.J., OhS.K.W.Immortalized feeders for the scale-up of human embryonic stem cells in feeder and feeder-free conditions. J Biotechnol, 122:130. 2006.
37.
SaitoM., HottaA., AsaiY.QTempo: a more sensitive, accurate alternative to the hERG assay utilizing human iPS cell-derived beating cardiomyocytes. Presented at the Stem Cells and Regenerative Medicine Europe, London, UK, 2009.
38.
UngrinM.D., JoshiC., NicaA., BauwensC., ZandstraP.W.Reproducible, ultra high-throughput formation of multicellular organization from single cell suspension-derived human embryonic stem cell aggregates. PLoS One, 3:1565. 2008.
39.
BauwensC.L., PeeraniR., NiebrueggeS., WoodhouseK.A., KumachevaE., HusainM., ZandstraP.W.Control of human embryonic stem cell colony and aggregate size heterogeneity influences differentiation trajectories. Stem Cells, 26:2300. 2008.
40.
YamamotoK., NunoiK., FujishimaM.Ultracentrifugation study on interactions among calmodulin, cardiac troponin and tropomyosin-actin complex. J Mol Cell Cardiol, 22:279. 1990.
41.
PaulinD., LiZ.Desmin: a major intermediate filament protein essential for the structural integrity and function of muscle. Exp Cell Res, 301:1. 2004.
42.
LiZ., MericskayM., AgbulutO., Butler-BrowneG., CarlssonL., ThornellL.E., BabinetC., PaulinD.Desmin is essential for the tensile strength and integrity of myofibrils but not for myogenic commitment, differentiation, and fusion of skeletal muscle. J Cell Biol, 139:129. 1997.
43.
ZhangJ., WilsonG.F., SoerensA.G., KoonceC.H., YuJ., PalecekS.P., ThomsonJ.A., KampT.J.Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res, 104:30. 2009.
44.
ReuvenyS.Microcarriers for culturing mammalian cells and their applications. Adv Biotechnol Process, 2:1. 1983.
PhillipsB.W., LimR.Y.M., TanT.T., RustW.L., CrookJ.M.Efficient expansion of clinical-grade human fibroblasts on microcarriers: cells suitable for ex vivo expansion of clinical-grade hESCs. J Biotechnol, 134:79. 2008.
47.
FernandesA.M., FernandesT.G., DiogoM.M., da SilvaC.L., HenriqueD., CabralJ.M.S.Mouse embryonic stem cell expansion in a microcarrier-based stirred culture system. J Biotechnol, 132:227. 2007.
48.
AbranchesE., BekmanE., HenriqueD., CabralJ.M.S.Expansion of mouse embryonic stem cells on microcarriers. Biotechnol Bioeng, 96:1211. 2007.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
